Cargando…

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease

BACKGROUND: The inflammatory biomarker YKL‐40 has previously been studied as a potential risk marker in cardiovascular disease. We aimed to assess the prognostic reclassification potential of serum YKL‐40 in patients with stable coronary artery disease. METHODS AND RESULTS: The main study population...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroder, Jakob, Jakobsen, Janus Christian, Winkel, Per, Hilden, Jørgen, Jensen, Gorm Boje, Sajadieh, Ahmad, Larsson, Anders, Ärnlöv, Johan, Harutyunyan, Marina, Johansen, Julia S., Kjøller, Erik, Gluud, Christian, Kastrup, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335588/ https://www.ncbi.nlm.nih.gov/pubmed/32114892 http://dx.doi.org/10.1161/JAHA.119.014634

Ejemplares similares

Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial
por: Winkel, Per, et al.
Publicado: (2017)

Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course
por: Winkel, Per, et al.
Publicado: (2018)

Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial
por: Winkel, Per, et al.
Publicado: (2020)

10‐Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy
por: Carlsson, Axel C., et al.
Publicado: (2018)

Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up—A CLARICOR Trial Sub-Study
por: Nilsson, Erik, et al.
Publicado: (2020)

Power estimations for non-primary outcomes in randomised clinical trials
por: Jakobsen, Janus Christian, et al.
Publicado: (2019)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

A polymorphism associated with increased levels of YKL-40 and the risk of early onset of lone atrial fibrillation
por: Henningsen, Kristoffer M A, et al.
Publicado: (2013)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
por: Jakobsen, Janus Christian, et al.
Publicado: (2017)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

The thresholds for statistical and clinical significance – a five-step procedure for evaluation of intervention effects in randomised clinical trials
por: Jakobsen, Janus Christian, et al.
Publicado: (2014)

Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods
por: Jakobsen, Janus Christian, et al.
Publicado: (2014)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
por: Gevezova, Maria, et al.
Publicado: (2023)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

SSEA‐4 and YKL‐40 positive progenitor subtypes in the subventricular zone of developing human neocortex
por: Brøchner, Christian B., et al.
Publicado: (2015)

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
por: Shao, Rong, et al.
Publicado: (2009)

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis
por: Shao, Rong
Publicado: (2013)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model
por: Kocabas, Rahim
Publicado: (2023)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
por: Olsen, Markus Harboe, et al.
Publicado: (2021)

Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
por: Kim, Steve H, et al.
Publicado: (2007)

YKL-40 levels are independently associated with albuminuria in type 2 diabetes
por: Røndbjerg, Anne K, et al.
Publicado: (2011)

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension
por: Wang, Dong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jlqhdamjga56t9q2ifnegpvc2k